Table 1.

Characteristics of studies included in the meta-analysis.

First author (year)	NCT number	Number of patients (E5/E15/C)	Baseline HbA1c	Intervention	Control	Periods
Ji (2019) [14]	NCT: 02630706	170/169/167	7.0-10.5%	1. Ertugliflozin 5 mg; 2. ertugliflozin 15 mg GRT: glimepiride	Placebo	26 weeks
Rosenstock (2018) [6], Gallo (2019) [16]	NCT: 02033889	207/205/209	7.0-10.5%	1. Ertugliflozin 5 mg; 2. ertugliflozin 15 mg GRT: glimepiride (1-26 weeks), basal insulin (27-104 weeks)	Placebo	26 weeks, 104 weeks
Hollander (2018) [18], Hollander (2019) [15]	NCT: 01999218	488/440/437	7.0-9.0%	1. Ertugliflozin 5 mg; 2. ertugliflozin 15 mg GRT: sitagliptin (1-52 weeks), not permitted (53-104 weeks)	Glimepiride up to 6 or 8 mg/d	52 weeks, 104 weeks
Pratley (2018) [17]	NCT: 02099110	250/248/247	7.5-11%	1. Ertugliflozin 5 mg; 2. ertugliflozin 15 mg GRT: glimepiride or glargine	Sitagliptin 100 mg	26 weeks, 52 weeks
Terra (2017) [21], Aronson (2018) [20]	NCT: 01958671	156/152/153	7.0-10.5%	1. Ertugliflozin 5 mg; 2. ertugliflozin 15 mg GRT: metformin (1-26 weeks), glimepiride (27-52 weeks)	Placebo (1-26 weeks), metformin (27-52 weeks)	26 weeks, 52 weeks
Dagogo-Jack (2018) [19]	NCT: 02036515	156/153/153	7.0-10.5%	1. Ertugliflozin 5 mg; 2. ertugliflozin 15 mg GRT: glimepiride or glargine	Placebo	26 weeks, 52 weeks

E5: ertugliflozin 5 mg; E15: ertugliflozin 15 mg; C: control; GRT: glycemic rescue therapy.